<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   High-flow nasal cannula oxygen therapy in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       High-flow nasal cannula oxygen therapy in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        High-flow nasal cannula oxygen therapy in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joshua Nagler, MD, MHPEd
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Torrey, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Wiley, II, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 12, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3126328984">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic will focus on the use of high-flow nasal cannula (HFNC) in pediatric patients, including discussion of equipment, proposed mechanisms of action, comparison with other oxygen delivery devices, indications and contraindications, approach to initiation, assessment of effectiveness, and potential complications.
        </p>
        <p>
         The use of HFNC for bronchiolitis and for premature and term neonates is discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">
          "Bronchiolitis in infants and children: Treatment, outcome, and prevention", section on 'Noninvasive ventilation'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5067.html" rel="external">
          "Respiratory support, oxygen delivery, and oxygen monitoring in the newborn", section on 'High-flow nasal cannula'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2187864906">
         <span class="h1">
          DESCRIPTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFNC oxygen therapy, also referred to as heated, humidified, high-flow nasal cannula (HHHFNC), involves the delivery of an adjustable mixture of heated and humidified air and oxygen at rates that exceed spontaneous inspiratory flow. There is no single definition of what constitutes high flow, as rates will vary by the age and weight of the patient, with a range of 2 to 60 L/min. The use of HFNC has been increasing over time as equipment has become more widely available and indications for use have grown [
         <a href="#rid1">
          1-4
         </a>
         ]. In addition, HFNC is easy to apply and well tolerated by most patients, furthering the appeal. While originally restricted to intensive care units, its use has now expanded to emergency departments, inpatient pediatric wards, and pre- and interhospital transport settings [
         <a href="#rid5">
          5-11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H288174492">
         <span class="h1">
          EQUIPMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFNC systems include a number of parts  (
         <a class="graphic graphic_figure graphicRef127005" href="/z/d/graphic/127005.html" rel="external">
          figure 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Generator to create flow
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blender to mix air and oxygen
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chamber to condition (ie, heat and humidify) the air
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Circuit to reach the patient
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient interface (eg, nasal cannula or prongs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pressure-relief valve (optional safety mechanism to stop flow when a predetermined pressure is reached)
        </p>
        <p>
        </p>
        <p>
         Nebulized therapy such as bronchodilators [
         <a href="#rid12">
          12-15
         </a>
         ] as well as helium-oxygen mixtures and
         <a class="drug drug_pediatric" data-topicid="106992" href="/z/d/drug information/106992.html" rel="external">
          inhaled nitric oxide
         </a>
         [
         <a href="#rid16">
          16-18
         </a>
         ] can be delivered using HFNC, although data regarding efficacy and safety are limited to in vitro studies and small pediatric case series. Furthermore, the rate of delivery of medication is difficult to estimate and is likely to be reduced at higher flow rates [
         <a href="#rid14">
          14
         </a>
         ]; improved clinical outcomes have not been demonstrated compared with jet nebulization. For these reasons, we do not routinely deliver medication using HFNC.
        </p>
        <p class="headingAnchor" id="H2026060363">
         <span class="h1">
          MECHANISMS OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are a number of proposed mechanisms by which HFNC might be beneficial for infants and children with respiratory illness, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Washout of nasopharyngeal dead space
         </strong>
         – High-flow delivery washes out the end-expiratory gas within the oro- and nasopharynx. The upper airway then serves as an anatomic reservoir with richly oxygenated air from which the patient draws each breath, minimizing the entrainment of room air [
         <a href="#rid19">
          19-22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reduction in upper airway resistance
         </strong>
         – By providing gas flows that match or exceed spontaneous inspiratory flow rates, HFNC minimizes inspiratory resistance across the nasopharynx. The resultant reduction in work of breathing has been demonstrated in studies in neonates and infants by measuring diaphragmatic electrical activity and respiratory plethysmography [
         <a href="#rid21">
          21,23-25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optimal conditioning of gas
         </strong>
         – Delivering gases that have been previously heated and humidified reduces the energy expenditure required by the body for conditioning. This is particularly valuable for children with respiratory illness who may be tachypneic and rapidly turning over their tidal volume because optimal conditioning contributes to reductions in oxygen demand [
         <a href="#rid21">
          21
         </a>
         ]. It also avoids an increased risk of bronchospasm and airway resistance compared with the delivery of cold, dry air [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positive distending pressure
         </strong>
         – High flow rates provide positive distending pressure in the pharynx, which can prevent collapse and improve work of breathing. The amount of pressure varies based on flow rate, fit of the nasal prongs, and mouth opening [
         <a href="#rid27">
          27
         </a>
         ]. In a study of infants with bronchiolitis, a flow rate of 2 L/kg per minute resulted in mean pharyngeal pressures &gt;4 cm H
         <sub>
          2
         </sub>
         O and improved breathing [
         <a href="#rid28">
          28
         </a>
         ]. In adults, a linear relationship is noted between flow rates and pharyngeal pressure, ranging from 1 to 4 cm H
         <sub>
          2
         </sub>
         O when the mouth is closed  (
         <a class="graphic graphic_figure graphicRef115104" href="/z/d/graphic/115104.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/114077.html" rel="external">
          "Heated and humidified high-flow nasal oxygen in adults: Practical considerations and potential applications"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of mouth opening
         </strong>
         – Studies in children have documented a difference in increased pharyngeal pressure during HFNC when the mouth is closed compared with when it is open [
         <a href="#rid27">
          27,29
         </a>
         ]. Therefore, in infants, concurrent use of a pacifier may be helpful in achieving the full benefit of HFNC.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2811580938">
         <span class="h1">
          COMPARISON WITH OTHER MODES OF OXYGEN DELIVERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFNC offers distinct advantages over other modes of oxygen delivery and respiratory support without compromising ease of initiation or patient comfort. Many of the clinical trials comparing these approaches have been performed in patients with bronchiolitis. (See
         <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">
          "Bronchiolitis in infants and children: Treatment, outcome, and prevention", section on 'Noninvasive ventilation'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low-flow nasal cannula
         </strong>
         – Flow rates through nasal cannula have traditionally been limited to low flow (&lt;2 L/min in infants and &lt;6 L/min in children) to avoid desiccation of the nasal mucosa and discomfort to the patient. Humidifying and heating the gas mixtures reduces these concerns and permits delivery of higher flow rates and improved oxygen delivery. In addition, the HFNC blender allows for adjustment of the concentration of inspired oxygen rather than just adjustment in flow. For example, an observational study in 40 children with moderate to severe bronchiolitis (in contrast to bronchiolitis generally) showed more rapid improvements in respiratory rate, work of breathing, and ability to feed in infants treated with HFNC compared with low-flow nasal cannula [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Face mask
         </strong>
         – Face masks are often perceived as constricting, limit the ability to speak or drink, and are not well tolerated by many pediatric patients. In addition, HFNC has been shown to provide better oxygen delivery than face masks. The majority of comparative trials have been performed following extubation [
         <a href="#rid31">
          31,32
         </a>
         ]; however, one study of adult patients with hypoxemic respiratory failure found higher partial pressure of oxygen (PaO
         <sub>
          2
         </sub>
         ) concentrations when managed with HFNC compared with oxygen delivery using a face mask [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Masks with diffuser
         </strong>
         – OxyMask is a specialized face mask that directs oxygen toward the nose and mouth using a diffuser system (see
         <a class="medical medical_review" href="/z/d/html/6394.html" rel="external">
          "Continuous oxygen delivery systems for the acute care of infants, children, and adults", section on 'Face masks'
         </a>
         ). The open design has the potential to be less frightening to pediatric patients yet deliver high concentrations of oxygen. However, HFNC, in addition to being well-tolerated by pediatric patients, provides positive pressure, which may make it a better choice for oxygen delivery in patients with specific conditions, such as bronchiolitis. As an example, in a randomized controlled trial of 60 infants with moderate to severe bronchiolitis receiving treatment in an intensive care unit, individuals receiving HFNC rather than the OxyMask had fewer treatment failures (0 versus 7, respectively) and were weaned from oxygen sooner (56 versus 96 hours) [
         <a href="#rid34">
          34
         </a>
         ]. This result likely reflects the benefits of positive pharyngeal pressure and conditioning that are provided by HFNC. (See
         <a class="local">
          'Mechanisms of action'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Noninvasive ventilation (CPAP)
         </strong>
         – Continuous positive airway pressure (CPAP) offers airway-distending pressure that can help with work of breathing and oxygenation for children with respiratory disease. Most comparative studies between CPAP and HFNC have been performed in patients with bronchiolitis. (See
         <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">
          "Bronchiolitis in infants and children: Treatment, outcome, and prevention", section on 'Noninvasive ventilation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other studies have compared these therapies for other diagnoses as well. For example, HFNC appears to be at least as good as CPAP for pediatric patients requiring noninvasive respiratory support and may be better tolerated by the patient. In an unblinded, multicenter trial of over 570 infants (median age 9 to 10 months) assessed to require noninvasive respiratory support and randomly assigned to HFNC or CPAP for their underlying condition (approximately 50 percent with bronchiolitis; 20 to 25 percent with asthma, upper airway problem, or other respiratory condition; and the rest with nonrespiratory conditions including sepsis), the duration of noninvasive respiratory support and the proportion requiring endotracheal intubation were similar in both groups [
         <a href="#rid35">
          35
         </a>
         ]. Patients assigned to HFNC had significantly lower use of sedation (28 versus 37 percent), shorter mean duration of intensive care unit stay (5 versus 7.4 days), and shorter mean duration of hospitalization (13.8 versus 19.4 days). Patients assigned to CPAP had more nasal trauma. These findings contrast with results from smaller trials in patients with respiratory conditions other than bronchiolitis that have suggested shorter time to improvement and reduced need for change in respiratory management for CPAP compared with HFNC [
         <a href="#rid36">
          36,37
         </a>
         ]. However, in addition to the higher risk of nasal trauma for patients receiving CPAP described above, CPAP is also louder than HFNC, not always tolerated by young infants, and may increase the risk of skin breakdown [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1629511800">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFNC may be trialed in any patient with severe respiratory distress or hypoxemia who can maintain their airway (alert and able to swallow), and who does not have other contraindications. (See
         <a class="local">
          'Contraindications'
         </a>
         below.)
        </p>
        <p>
         HFNC offers many of the benefits of noninvasive positive-pressure ventilation and is often easy to initiate and frequently well tolerated by children. It may prevent progression to noninvasive or mechanical ventilation in selected patients. The majority of clinical experience for HFNC outside of neonates comes from management of patients with bronchiolitis. The use of HFNC for the treatment of bronchiolitis is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6020.html" rel="external">
          "Bronchiolitis in infants and children: Treatment, outcome, and prevention", section on 'Noninvasive ventilation'
         </a>
         .)
        </p>
        <p>
         Other respiratory conditions where HFNC may have a potential benefit include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory distress/dyspnea
         </strong>
         – HFNC has the ability to offload the work of breathing; therefore, it may be used in patients with dyspnea who are not responsive to alternative means of oxygen delivery or disease-specific therapies (eg, bronchodilators for status asthmaticus or racemic
         <a class="drug drug_pediatric" data-topicid="13272" href="/z/d/drug information/13272.html" rel="external">
          epinephrine
         </a>
         for croup). Trials suggest that HFNC can reduce respiratory distress and improve oxygen saturation in infants and children with respiratory distress from a variety of causes [
         <a href="#rid8">
          8,35,36,38
         </a>
         ]. However, a significant proportion of these patients are at risk for treatment failure, necessitating endotracheal intubation and mechanical ventilation (up to 15 percent of critically ill patients in one trial) [
         <a href="#rid35">
          35
         </a>
         ]. Thus, close monitoring and frequent reassessment is an essential component of proper delivery of HFNC. (See
         <a class="local">
          'Assessment of effectiveness'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asthma
         </strong>
         – Although evidence is limited, HFNC has been safely used for children with status asthmaticus as described separately. (See
         <a class="medical medical_review" href="/z/d/html/5747.html" rel="external">
          "Acute severe asthma exacerbations in children younger than 12 years: Intensive care unit management", section on 'High-flow nasal cannula'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tracheomalacia
         </strong>
         –
         <strong>
         </strong>
         HFNC has the potential to generate airway-distending pressure, which has been described in case reports for patients with tracheomalacia. (See
         <a class="medical medical_review" href="/z/d/html/6377.html" rel="external">
          "Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoxygenation/apneic oxygenation during intubation
         </strong>
         – Data for apneic oxygenation in children are currently limited; however, integration into practice is increasing. HFNC has potential advantages as a system for oxygenation delivery prior to and during endotracheal intubation as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increased oxygen delivery compared with other modes of oxygenation during intubation (see
         <a class="local">
          'Comparison with other modes of oxygen delivery'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduced bronchospasm (humidified, heated gas delivery)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No change of oxygen-delivery equipment needed when preparing to escalate care to endotracheal intubation and mechanical ventilation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The benefit of HFNC as a tool for preoxygenation or apneic oxygenation needs to be weighed against potential downsides, including the delay in setup if not already in place, the possibility of gastric distension, and the inability to create an effective mask seal over the larger nasal cannula were mask ventilation to be required during the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a small trial of 48 children requiring intubation for elective surgery or advanced imaging, the addition of HFNC oxygen delivery (range of flow rates from 2 to 50 L/min) as part of the induction protocol increased oxygenated apnea time compared with routine induction with standardized bag-mask ventilation (192 versus 109 seconds, respectively) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypoxemic respiratory failure
         </strong>
         – HFNC oxygen therapy appears to provide support similar to CPAP for children with hypoxemic respiratory failure. For example, in a multicenter trial of HFNC versus CPAP in critically ill children, HFNC was similar to CPAP for time to liberation from respiratory support and need for endotracheal intubation; over 40 percent of patients had an oxygen requirement consistent with pediatric acute respiratory distress syndrome [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, HFNC oxygen therapy may not have better efficacy than standard oxygen therapy for children with mild to moderate acute hypoxemic respiratory failure (AHRF). For example, in the multicenter PARIS-2 trial of over 1500 children (median age 1.9 years) hospitalized with mild to moderate acute hypoxemic respiratory failure defined as increased work of breathing, respiratory rate ≥35 per minute, and oxygen requirement to maintain pulse oximetry over 90 to 92 percent, patients assigned to HFNC oxygen therapy, compared with standard oxygen therapy, had longer length of stay (1.77 versus 1.5 days) and more ICU admissions (12.5 versus 6.9 percent, adjusted odds ratio [aOR] 1.9, 95% CI 1.4-2.8) [
         <a href="#rid40">
          40,41
         </a>
         ]. Adverse events were low in both groups. These findings do not support the routine use of HFNC oxygen therapy in young children with mild to moderate acute hypoxemic respiratory failure.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3904233797">
         <span class="h1">
          CONTRAINDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFNC should not delay advanced airway management in a patient deemed to require immediate endotracheal intubation. This may include patients with acutely impaired mental status, risk of aspiration, or other need for airway protection.
        </p>
        <p>
         HFNC should also be
         <strong>
          avoided
         </strong>
         in the following conditions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypercapnic respiratory failure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Facial anomalies (eg, choanal atresia) or injuries that preclude appropriate nasal cannula fit
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excessive oral or nasal secretions
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Active vomiting
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bowel obstruction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Existing air leak (eg, pneumothorax or pneumomediastinum)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agitation or confusion predicting inability to tolerate
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2269191044">
         <span class="h1">
          PATIENT SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Appropriate patient selection is essential to the successful use of HFNC. Before initiating its use, all of the following should be determined:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No contraindications to HFNC (see
         <a class="local">
          'Contraindications'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High likelihood that the patient will tolerate HFNC (commonly well tolerated in children)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reasonable expectation that HFNC will be adequate to stabilize and/or reverse the current respiratory status (see
         <a class="local">
          'Indications'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3643444410">
         <span class="h1">
          INITIATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFNC is relatively simple to initiate. After an appropriately sized nasal cannula and circuit is selected for the patient, the clinician can determine delivery settings, including air temperature, flow rate, and fraction of inspired oxygen (FiO
         <sub>
          2
         </sub>
         ). Humidification varies with chosen air temperature. Initial flow rates and FiO
         <sub>
          2
         </sub>
         will vary by age/size of patient and indication/severity of disease, and they can be increased pending response to initial settings.
        </p>
        <p class="headingAnchor" id="H931393031">
         <span class="h2">
          COVID-19 precautions
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFNC oxygen therapy is considered an aerosol-generating procedure. Thus, appropriate infection control precautions are required when it is being administered to patients with unknown or positive coronavirus disease 2019 (COVID-19) status as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">
          "COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Aerosol-generating procedures/treatments'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/131226.html" rel="external">
          "COVID-19: Respiratory care of the nonintubated hypoxemic adult (supplemental oxygen, noninvasive ventilation, and intubation)", section on 'Infection control precautions for noninvasive modalities'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2795241541">
         <span class="h2">
          Cannula selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cannulae used to deliver high flow do not require a seal to function and therefore have prongs with smaller diameter and length than interfaces designed for continuous positive airway pressure (CPAP).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recommendations are for the cannula to occupy approximately 50 percent of the internal diameter of the nares to permit some leak and prevent excessive airway pressure [
         <a href="#rid42">
          42,43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The distance between the prongs should be wide enough to avoid pinching the nasal septum.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2393529836">
         <span class="h2">
          Initial settings
         </span>
         <span class="headingEndMark">
          —
         </span>
         HFNC settings can be started based on perceived need and adjusted based on clinical response as measured by work of breathing and continuously monitored heart rate, respiratory rate, and oxygen saturation [
         <a href="#rid44">
          44-46
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Temperature is commonly set at 37°C to maximize humidification, although this may be adjusted based on clinical context.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial flow rates should be based on patient age or size and advanced as needed. The table offers suggested initial and maximal flow rates  (
         <a class="graphic graphic_table graphicRef122857" href="/z/d/graphic/122857.html" rel="external">
          table 1
         </a>
         ). Alternatively, flow rates can be started at 1 to 2 L/kg per minute up to the maximum flow rate for age. A study of children younger than three years of age showed that work of breathing was improved with increasing flow rates with maximal improvement at 2 L/kg per minute but similar improvement at 1.5 L/kg per minute.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FiO
         <sub>
          2
         </sub>
         can be set between 0.21 and 1 based on clinical circumstance. General practice is a goal oxygen saturation between 94 and 99 percent rather than 100 percent (to avoid oxygen toxicity).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2257007984">
         <span class="h2">
          Assessment of effectiveness
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of metrics can be used to assess the patient response to HFNC therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vital signs
         </strong>
         – Infants started on HFNC therapy often show improvement in heart rate and respiratory rate (specifically reduced tachycardia and tachypnea) as early signs of responsiveness [
         <a href="#rid6">
          6,7,28,30
         </a>
         ]. Responsiveness may be seen within the first hour of therapy, though in some individuals, it may take several hours before improvement is evident.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Work of breathing
         </strong>
         – HFNC can significantly offload work of breathing. Electrical activity of the diaphragm and decreased swings in esophageal pressure can document such physiologic changes but are not useful clinically [
         <a href="#rid23">
          23
         </a>
         ]. Pediatric scoring systems to guide clinical assessment are available, such as disease-specific respiratory scores for bronchiolitis and asthma  (
         <a class="graphic graphic_table graphicRef53797" href="/z/d/graphic/53797.html" rel="external">
          table 2
         </a>
         ) as well as general respiratory distress scores. (See
         <a class="medical medical_review" href="/z/d/html/6018.html" rel="external">
          "Bronchiolitis in infants and children: Clinical features and diagnosis", section on 'Severity assessment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oxygen requirement
         </strong>
         – Oxygenation should improve following the initiation of HFNC. In one study, an oxygen saturation (SpO
         <sub>
          2
         </sub>
         )/FiO
         <sub>
          2
         </sub>
         ratio of &gt;200 at 60 minutes was associated with successful therapy with HFNC [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H367266143">
         <span class="h1">
          COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence is limited regarding the safety of HFNC therapy for respiratory support in children [
         <a href="#rid48">
          48
         </a>
         ]. However, despite increasing use in multiple settings, reported serious complications from HFNC therapy are limited to case reports of air leak and pneumocephalus [
         <a href="#rid49">
          49,50
         </a>
         ], and rates of adverse events are lower than with continuous positive airway pressure (CPAP) and comparable to standard oxygen therapy (&lt;1 percent) [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         The risk of complications secondary to high airway pressure and traumatic air dissection can be further reduced with pressure-relief valves built into some HFNC systems. In addition, using the lowest effective flow rates and ensuring appropriate selection of nasal cannula size to allow sufficient leak can be protective [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3378031263">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – High-flow nasal cannula (HFNC) oxygen therapy  (
         <a class="graphic graphic_figure graphicRef127005" href="/z/d/graphic/127005.html" rel="external">
          figure 1
         </a>
         ), also referred to as heated, humidified, high-flow nasal cannula (HHHFNC), involves the delivery of an adjustable mixture of heated and humidified air and oxygen at rates that exceed spontaneous inspiratory flow. There is no single definition of what constitutes high flow because rates will vary by the age and weight of the patient, with a range of 2 to 60 L/min. (See
         <a class="local">
          'Description'
         </a>
         above and
         <a class="local">
          'Equipment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Benefits
         </strong>
         – HFNC oxygen therapy offers distinct advantages over other modes of oxygen delivery and respiratory support without compromising ease of initiation or patient comfort, including better oxygen delivery than low-flow nasal cannula, face mask, or mask with diffuser systems and better comfort than noninvasive ventilation. (See
         <a class="local">
          'Comparison with other modes of oxygen delivery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – HFNC oxygen therapy may be trialed in any patient who can maintain their airway (alert and able to swallow), who does not have contraindications to its use as described below, and who has severe respiratory distress or hypoxemia. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         – HFNC oxygen therapy should not delay advanced airway management in a patient deemed to require immediate endotracheal intubation. This may include patients with acutely impaired mental status, risk of aspiration, or other need for airway protection. (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         HFNC oxygen therapy should also be
         <strong>
          avoided
         </strong>
         in the following conditions (see
         <a class="local">
          'Contraindications'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypercapnic respiratory failure
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Facial anomalies (eg, choanal atresia) or injuries that preclude appropriate nasal cannula fit
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Excessive oral or nasal secretions
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Active vomiting
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bowel obstruction
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Existing air leak (eg, pneumothorax or pneumomediastinum)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Agitation or confusion predicting inability to tolerate
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Procedure
         </strong>
         – Initiation of HFNC oxygen therapy is described in detail in the topic. After an appropriately sized nasal cannula and circuit is selected for the patient, the clinician can determine delivery settings, including air temperature (typically 37°C), flow rate, and fraction of inspired oxygen (FiO
         <sub>
          2
         </sub>
         ). Humidification varies with chosen air temperature. (See
         <a class="local">
          'Initiation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Initial flow rates and
         <sub>
          F
         </sub>
         iO
         <sub>
          2
         </sub>
         will vary by age/size of the patient  (
         <a class="graphic graphic_table graphicRef122857" href="/z/d/graphic/122857.html" rel="external">
          table 1
         </a>
         ) and indication/severity of disease, and they can be adjusted pending response to initial settings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Response to therapy can be measured by evaluating for improvement in vital signs (eg, decreased tachycardia and/or tachypnea), decreased work of breathing, and improved oxygenation. (See
         <a class="local">
          'Assessment of effectiveness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Serious complications, such as pneumothorax, can occur with HFNC oxygen delivery, but the rates of adverse events are comparable with standard oxygen therapy (&lt;1 percent) and are less than what is reported in patients receiving continuous positive airway pressure (CPAP) or mechanical ventilation. (See
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Miller AG, Gentle MA, Tyler LM, Napolitano N. High-Flow Nasal Cannula in Pediatric Patients: A Survey of Clinical Practice. Respir Care 2018; 63:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wraight TI, Ganu SS. High-flow nasal cannula use in a paediatric intensive care unit over 3 years. Crit Care Resusc 2015; 17:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hutchings FA, Hilliard TN, Davis PJ. Heated humidified high-flow nasal cannula therapy in children. Arch Dis Child 2015; 100:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JH, Rehder KJ, Williford L, et al. Use of high flow nasal cannula in critically ill infants, children, and adults: a critical review of the literature. Intensive Care Med 2013; 39:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wing R, James C, Maranda LS, Armsby CC. Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. Pediatr Emerg Care 2012; 28:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bressan S, Balzani M, Krauss B, et al. High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study. Eur J Pediatr 2013; 172:1649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayfield S, Bogossian F, O'Malley L, Schibler A. High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study. J Paediatr Child Health 2014; 50:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly GS, Simon HK, Sturm JJ. High-flow nasal cannula use in children with respiratory distress in the emergency department: predicting the need for subsequent intubation. Pediatr Emerg Care 2013; 29:888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyle M, Chaudhary R, Kent S, et al. High-flow nasal cannula on  transport: moving with the  times. Acta Paediatr 2014; 103:e181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riese J, Porter T, Fierce J, et al. Clinical Outcomes of Bronchiolitis After Implementation of a General Ward High Flow Nasal Cannula Guideline. Hosp Pediatr 2017; 7:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosheh O, Edwards CT, Ramnarayan P. A nationwide survey on the use of heated humidified high flow oxygen therapy on the paediatric wards in the UK: current practice and research priorities. BMC Pediatr 2020; 20:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan SE, Mosakowski S, Solano P, et al. High-Flow Nasal Cannula and Aerosolized β Agonists for Rescue Therapy in Children With Bronchiolitis: A Case Series. Respir Care 2015; 60:e161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valencia-Ramos J, Mirás A, Cilla A, et al. Incorporating a Nebulizer System Into High-Flow Nasal Cannula Improves Comfort in Infants With Bronchiolitis. Respir Care 2018; 63:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Subu AM, Hagen S, Eldridge M, Boriosi J. Aerosol therapy through high flow nasal cannula in pediatric patients. Expert Rev Respir Med 2017; 11:945.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Subu AM, Nguyen VT, AlAli Y, et al. Feasibility of Aerosol Bronchodilators Delivery Through High-Flow Nasal Cannula in Pediatric Subjects With Respiratory Distress. Respir Care 2020; 65:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgan SE, Vukin K, Mosakowski S, et al. Use of heliox delivered via high-flow nasal cannula to treat an infant with coronavirus-related respiratory infection and severe acute air-flow obstruction. Respir Care 2014; 59:e166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry SA, Kesser KC, Geller DE, et al. Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system. Pediatr Crit Care Med 2013; 14:e250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ismail A, Sharara-Chami R, El-Khatib M. Combination of high-flow nasal cannula oxygen therapy and inhaled nitric oxide in a paediatric patient with respiratory distress. Anaesth Intensive Care 2014; 42:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Möller W, Celik G, Feng S, et al. Nasal high flow clears anatomical dead space in upper airway models. J Appl Physiol (1985) 2015; 118:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nieves A, Cozzo A, Kosoff Z, et al. 3D airway model to assess airway dead space. Arch Dis Child Fetal Neonatal Ed 2019; 104:F321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dysart K, Miller TL, Wolfson MR, Shaffer TH. Research in high flow therapy: mechanisms of action. Respir Med 2009; 103:1400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frizzola M, Miller TL, Rodriguez ME, et al. High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model. Pediatr Pulmonol 2011; 46:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pham TM, O'Malley L, Mayfield S, et al. The effect of high flow nasal cannula therapy on the work of breathing in infants with bronchiolitis. Pediatr Pulmonol 2015; 50:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jongh BE, Locke R, Mackley A, et al. Work of breathing indices in infants with respiratory insufficiency receiving high-flow nasal cannula and nasal continuous positive airway pressure. J Perinatol 2014; 34:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saslow JG, Aghai ZH, Nakhla TA, et al. Work of breathing using high-flow nasal cannula in preterm infants. J Perinatol 2006; 26:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontanari P, Burnet H, Zattara-Hartmann MC, Jammes Y. Changes in airway resistance induced by nasal inhalation of cold dry, dry, or moist air in normal individuals. J Appl Physiol (1985) 1996; 81:1739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dani C, Pratesi S, Migliori C, Bertini G. High flow nasal cannula therapy as respiratory support in the preterm infant. Pediatr Pulmonol 2009; 44:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milési C, Baleine J, Matecki S, et al. Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. Intensive Care Med 2013; 39:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kubicka ZJ, Limauro J, Darnall RA. Heated, humidified high-flow nasal cannula therapy: yet another way to deliver continuous positive airway pressure? Pediatrics 2008; 121:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milani GP, Plebani AM, Arturi E, et al. Using a high-flow nasal cannula provided superior results to low-flow oxygen delivery in moderate to severe bronchiolitis. Acta Paediatr 2016; 105:e368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu Y, Yin H, Zhang R, et al. High-flow nasal cannula oxygen therapy versus conventional oxygen therapy in patients after planned extubation: a systematic review and meta-analysis. Crit Care 2019; 23:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maggiore SM, Idone FA, Vaschetto R, et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med 2014; 190:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwabbauer N, Berg B, Blumenstock G, et al. Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV). BMC Anesthesiol 2014; 14:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ergul AB, Calıskan E, Samsa H, et al. Using a high-flow nasal cannula provides superior results to OxyMask delivery in moderate to severe bronchiolitis: a randomized controlled study. Eur J Pediatr 2018; 177:1299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramnarayan P, Richards-Belle A, Drikite L, et al. Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units: A Randomized Clinical Trial. JAMA 2022; 328:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitaliti G, Vitaliti MC, Finocchiaro MC, et al. Randomized Comparison of Helmet CPAP Versus High-Flow Nasal Cannula Oxygen in Pediatric Respiratory Distress. Respir Care 2017; 62:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramnarayan P, Lister P, Dominguez T, et al. FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): a multicentre pilot randomised controlled trial of high-flow nasal cannula therapy versus continuous positive airway pressure in paediatric critical care. Crit Care 2018; 22:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spentzas T, Minarik M, Patters AB, et al. Children with respiratory distress treated with high-flow nasal cannula. J Intensive Care Med 2009; 24:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humphreys S, Lee-Archer P, Reyne G, et al. Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) in children: a randomized controlled trial. Br J Anaesth 2017; 118:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franklin D, Babl FE, George S, et al. Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial. JAMA 2023; 329:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franklin D, Babl FE, Schibler A. High-Flow Nasal Oxygen vs Standard Oxygen Therapy and Length of Hospital Stay in Children With Acute Hypoxemic Respiratory Failure-Reply. JAMA 2023; 329:1611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sivieri EM, Gerdes JS, Abbasi S. Effect of HFNC flow rate, cannula size, and nares diameter on generated airway pressures: an in vitro study. Pediatr Pulmonol 2013; 48:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoder BA, Stoddard RA, Li M, et al. Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates. Pediatrics 2013; 131:e1482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cummings JJ, Polin RA, Committee on Fetus and Newborn, American Academy of Pediatrics. Noninvasive Respiratory Support. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milési C, Boubal M, Jacquot A, et al. High-flow nasal cannula: recommendations for daily practice in pediatrics. Ann Intensive Care 2014; 4:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiler T, Kamerkar A, Hotz J, et al. The Relationship between High Flow Nasal Cannula Flow Rate and Effort of Breathing in Children. J Pediatr 2017; 189:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safiri S, Qorbani M. Comments on "Predictive factors for the outcome of high flow nasal cannula therapy in a pediatric intensive care unit: Is the SpO2/FiO2 ratio useful?". J Crit Care 2018; 44:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayfield S, Jauncey‐Cooke J, Hough JL, et al. High‐flow nasal cannula therapy for respiratory support in children. Cochrane Libr 2014; 3:Cd009850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hegde S, Prodhan P. Serious air leak syndrome complicating high-flow nasal cannula therapy: a report of 3 cases. Pediatrics 2013; 131:e939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jasin LR, Kern S, Thompson S, et al. Subcutaneous scalp emphysema, pneumo-orbitis and pneumocephalus in a neonate on high humidity high flow nasal cannula. J Perinatol 2008; 28:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin J, Zhang Y, Xiong L, et al. High-flow nasal cannula therapy for children with bronchiolitis: a systematic review and meta-analysis. Arch Dis Child 2019; 104:564.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 122550 Version 12.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29535260" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : High-Flow Nasal Cannula in Pediatric Patients: A Survey of Clinical Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26282258" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : High-flow nasal cannula use in a paediatric intensive care unit over 3 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25452315" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Heated humidified high-flow nasal cannula therapy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23143331" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Use of high flow nasal cannula in critically ill infants, children, and adults: a critical review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23114231" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23900520" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24612137" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23903677" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : High-flow nasal cannula use in children with respiratory distress in the emergency department: predicting the need for subsequent intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24812714" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : High-flow nasal cannula on  transport: moving with the  times.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28292850" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical Outcomes of Bronchiolitis After Implementation of a General Ward High Flow Nasal Cannula Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32138701" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A nationwide survey on the use of heated humidified high flow oxygen therapy on the paediatric wards in the UK: current practice and research priorities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26106204" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : High-Flow Nasal Cannula and AerosolizedβAgonists for Rescue Therapy in Children With Bronchiolitis: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29844209" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Incorporating a Nebulizer System Into High-Flow Nasal Cannula Improves Comfort in Infants With Bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28994337" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Aerosol therapy through high flow nasal cannula in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31992665" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Feasibility of Aerosol Bronchodilators Delivery Through High-Flow Nasal Cannula in Pediatric Subjects With Respiratory Distress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25118308" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Use of heliox delivered via high-flow nasal cannula to treat an infant with coronavirus-related respiratory infection and severe acute air-flow obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23628834" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Influences of cannula size and flow rate on aerosol drug delivery through the Vapotherm humidified high-flow nasal cannula system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24967770" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Combination of high-flow nasal cannula oxygen therapy and inhaled nitric oxide in a paediatric patient with respiratory distress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25882385" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Nasal high flow clears anatomical dead space in upper airway models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30232093" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : 3D airway model to assess airway dead space.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19467849" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Research in high flow therapy: mechanisms of action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21171186" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : High-flow nasal cannula: impact on oxygenation and ventilation in an acute lung injury model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24846750" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The effect of high flow nasal cannula therapy on the work of breathing in infants with bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24071905" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Work of breathing indices in infants with respiratory insufficiency receiving high-flow nasal cannula and nasal continuous positive airway pressure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16688202" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Work of breathing using high-flow nasal cannula in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8904594" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Changes in airway resistance induced by nasal inhalation of cold dry, dry, or moist air in normal individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19499590" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : High flow nasal cannula therapy as respiratory support in the preterm infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23494016" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18166560" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Heated, humidified high-flow nasal cannula therapy: yet another way to deliver continuous positive airway pressure?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27102726" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Using a high-flow nasal cannula provided superior results to low-flow oxygen delivery in moderate to severe bronchiolitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31101127" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : High-flow nasal cannula oxygen therapy versus conventional oxygen therapy in patients after planned extubation: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25003980" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25110463" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Nasal high-flow oxygen therapy in patients with hypoxic respiratory failure: effect on functional and subjective respiratory parameters compared to conventional oxygen therapy and non-invasive ventilation (NIV).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29915869" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Using a high-flow nasal cannula provides superior results to OxyMask delivery in moderate to severe bronchiolitis: a randomized controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35707984" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effect of High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure Therapy on Liberation From Respiratory Support in Acutely Ill Children Admitted to Pediatric Critical Care Units: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28487415" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Randomized Comparison of Helmet CPAP Versus High-Flow Nasal Cannula Oxygen in Pediatric Respiratory Distress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29866165" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): a multicentre pilot randomised controlled trial of high-flow nasal cannula therapy versus continuous positive airway pressure in paediatric critical care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19703816" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Children with respiratory distress treated with high-flow nasal cannula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28100527" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) in children: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36648469" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37159036" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : High-Flow Nasal Oxygen vs Standard Oxygen Therapy and Length of Hospital Stay in Children With Acute Hypoxemic Respiratory Failure-Reply.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22825878" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Effect of HFNC flow rate, cannula size, and nares diameter on generated airway pressures: an in vitro study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23610207" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26715607" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Noninvasive Respiratory Support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25593745" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : High-flow nasal cannula: recommendations for daily practice in pediatrics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28669609" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The Relationship between High Flow Nasal Cannula Flow Rate and Effort of Breathing in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28992588" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comments on "Predictive factors for the outcome of high flow nasal cannula therapy in a pediatric intensive care unit: Is the SpO2/FiO2 ratio useful?"
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : High‐flow nasal cannula therapy for respiratory support in children
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23382446" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Serious air leak syndrome complicating high-flow nasal cannula therapy: a report of 3 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18974751" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Subcutaneous scalp emphysema, pneumo-orbitis and pneumocephalus in a neonate on high humidity high flow nasal cannula.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30655267" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : High-flow nasal cannula therapy for children with bronchiolitis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
